Abstract: B-cell acute lymphoblastic leukemia (ALL) is a hematological malignancy. Blinatumomab, as a therapeutic target, targeting CD19, has demonstrated notable efficacy as a safe bridge to allogeneic hematopoietic stem cell transplantation (allo-HSCT) in patients with relapsed/refractory acute lymphoblastic leukemia (R/R B-ALL). In the treatment of newly diagnosed ALL, blinatumomab, when combined with chemotherapy or other immunotherapies, reduces toxicity while ensuring efficacy. Similarly, combining blinatumomab with second- or third-generation tyrosine kinase inhibitors (TKIs) for the treatment of Philadelphia chromosome--positive (Ph⁺) ALL holds promise for eliminating the need for subsequent allo-HSCT in patients. Disease relapse and long-term survival of patients are closely related to minimal residual disease (MRD) at the conclusion of treatment, and blinatumomab contributes to enhancing the MRD conversion rate in patients with ALL, thus improving the long-term prognosis. This article comprehensively reviews the clinical trials and current progress of blinatumomab in various B-ALL patient groups.